Thomas F. Gajewski, M.D., Ph.D., directs the Melanoma Oncology Clinic and leads the Immunology and Cancer Program at the University of Chicago Comprehensive Cancer Center, and joined Zai’s Scientific Advisory Board in 2024.
Dr. Gajewski brings to our Board vast expertise in immunology and cancer research. His research has focused primarily on understanding fundamental aspects of anti-tumor immunity and translating these concepts into clinical trials. His work has been supported by funding from the National Institutes of Health (NIH) for two decades, and he is a scientific co-founder of Jounce Therapeutics and Pyxis Oncology.
Dr. Gajewski has published more than 240 manuscripts and 20 book chapters and has presented at more than 400 scientific conferences. He is the past president of the Society for Immunotherapy of Cancer and founding editor of the Journal for Immunotherapy of Cancer, and he has served on various NIH grant-review study sections as well as program committees for the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).
Dr. Gajewski and his work have been recognized through multiple awards, including the American Cancer Society-Jules L. Plangere Jr. Family Foundation Professorship in Cancer Immunotherapy, the William B. Coley Award and the European Society for Medical Oncology (ESMO) award in Immuno-oncology.
Dr. Gajewski received his Bachelor of Science, a Ph.D. in Immunology and an M.D. from the University of Chicago, where he also completed his residency and fellowship.
